Sullivan MA, et al. - Researchers performed a comparison of the outcomes of patients with opioid use disorder treated with long-acting injection naltrexone (XR-naltrexone) or oral naltrexone in combination with behavioral therapy in this open-label trial. They stratified 60 opioid-dependent adults by severity of opioid use (six or fewer bags vs more than six bags of heroin per day) and randomly assigned (1:1) them to continue treatment with oral naltrexone (N=32) or XR-naltrexone (N=28) for 24 weeks. Compared to patients receiving oral naltrexone, those receiving XR-naltrexone showed twice the rate of treatment retention at 6 months. Hence the use of XR-naltrexone combined with behavioral therapy is supported to be an effective treatment for patients seeking opioid withdrawal and nonagonist treatment for preventing relapse to opioid use disorder.